Trial Information

Summary: Future stroke risk reduction in patients with recent transient ischemic attack or stroke involving insulin resistance

Study Purpose: Platelets play a key role in the formation of plaques, which leads to hardening of the arteries and an increased risk of stroke. Aspirin (acetylsalicylic acid, or ASA) is an anti-platelet agent that has been shown to be effective in reducing the risk of stroke. Clopidogrel (Plavix®) is a different type of antiplatelet compound from aspirin, which is approximately as effective as aspirin in reducing the risk of stroke.

The purpose of this study is to determine if ASA and Plavix® is safe and more effective than Plavix® alone.

Study Procedures: The primary investigator, Dr. Samuel Markind; (or one of his associates from Associated Neurologists, PC of Danbury, CT) will perform a history and physical examination prior to entry into the study. If the patient is eligible for the study they may start taking study medication immediately. All study patients will receive Plavix® Patients will receive Plavix® 75 mg daily plus placebo or Plavix® 75 mg and aspirin 75 mg daily taken orally. Neither the study team nor the patient will know if they are receiving aspirin or placebo. Office visits will be required at 1 month, 3 months, 6 months, 12 months, and 18 months for follow-up. Patients will also be contacted monthly by telephone. No blood or urine samples will be required for participation in the study.

For Further Information:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.